Skip to content

The lived experience of people with von Willebrand disease

The lived experience of people with von Willebrand disease: a mixed methods study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ISRCTN
Registry ID
ISRCTN14289653
Enrollment
530
Registered
2023-08-24
Start date
2023-12-18
Completion date
Unknown
Last updated
2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

von Willebrand Disease (any known subgroup) Haematological Disorders

Interventions

All participants will be asked to complete an online survey. 30 participants will also be asked to take part in a single semi-structured qualitative interview. 50 participants will be asked to complet

Sponsors

Haemnet
Lead Sponsor

Eligibility

Sex/Gender
All
Age
16 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1. Adults aged 16 years and above (UK and Ireland) and adults aged over 18 years (in USA) with a confirmed diagnosis of inherited vWD of known diagnostic subtype and vWF level. 2. For the qualitative interview-based substudy, 30 adults who have completed the survey and who wish to be interviewed will be purposively selected for a broad range of ages and diagnostic subtype. 3. For the bleed diary substudy, 50 adults who have completed the survey and who wish to take part will be purposively selected for a broad range of ages and diagnostic subtype.

Exclusion criteria

Exclusion criteria: 1. Have acquired vWD 2. Have other inherited bleeding disorders 3. Do not wish to participate in or to consent to the study. 4. Are under 16 years old (UK & Ireland) or 18 years old (US). 5. Those for whom written/spoken English would prohibit participation will also be excluded.

Design outcomes

Primary

MeasureTime frame
Bleeding rates, daily activities, pain/discomfort and anxiety/depression will be measured using a retrospective, self-reported, validated survey (EQ-5D, Menstrual Impact Questionaire (for women) PHQ8 and GAD 7). This data will also be recorded prospectively using a 30 day bleed dairy.

Secondary

MeasureTime frame
Treatment satisfaction and assessment of unmet needs will be measured through analysis of the descriptive interview narratives of the lives of people with vWD collected at a single time point

Countries

England, Ireland, United Kingdom, United States of America

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 7, 2026